Sponsors
The bill improves clinical guidance and transparency to help responders treat a dangerous new class of opioids, but it provides no funding and creates administrative burdens that may limit effective implementation.
Emergency responders (firefighters/EMS) and hospital staff will receive standardized, evidence-based clinical protocols (including naloxone guidance) so they can recognize and treat nitazene overdoses faster and more effectively.
Rural and volunteer EMS services will get tailored guidance, improving access to evidence-based overdose care in underserved communities.
Congress and the public will receive timely information on nitazene risks and planned responses via a required report and a public website, improving transparency and oversight.
Guidelines do not provide funding for training or additional naloxone supplies, so frontline providers and communities may lack the resources to implement recommendations, limiting real-world impact.
Preparing and updating detailed clinical guidelines will impose administrative costs on HHS and could divert federal staff time from other priorities.
Based on analysis of 2 sections of legislative text.
Requires HHS to publish evidence-based clinical guidelines for responding to nitazene (ultra‑potent synthetic opioid) overdoses within 180 days and report to Congress within one year.
Introduced April 2, 2026 by David J. Taylor · Last progress April 2, 2026
Requires the Secretary of Health and Human Services to develop and publish evidence-based clinical guidelines for responding to overdoses from nitazenes—ultra‑potent synthetic opioids—and to post them on HHS’s public website within 180 days of enactment. The Secretary must also send Congress a report within one year that includes the guidelines and explains how they will help address nitazene overdoses. The legislation defines “nitazene” (benzimidazole-opioids similar to etonitazene and isotonitazene, with specific structural criteria and a list of named substances) and defines “nitazene overdose” as an overdose involving nitazene or any other ultra‑potent synthetic opioid. The guidance must include best practices such as naloxone administration protocols and tailored recommendations for emergency departments, hospitals, and rural or volunteer EMS providers. No new funding or mandates for states are specified.